Dr Paul Chrisp, director, Centre for Guidelines at NICE wasn't in Dr Seidu's session, but spoke toMedscape News UKabout whether NICE has plans to harmonise with ADA-EASD: "The short answer is no. "The longer answer is, where the evidence base shifts significantly, we look at that, ...
said: "Lenalidomide is a new type of targeted cancer therapy for people with previously treated follicular lymphoma. It not only offers patients a chemotherapy-free treatment option, but it also benefits those whose disease has become resistant to chemotherapy or rituximab. Lenalidomide fights cancer ...
It said clinical trial results show that ocrelizumab can slow the worsening of disability in people with the condition. However, the size and duration of this effect were uncertain and approval for the drug could not be justified on cost-effectiveness grounds, it said. Genevieve Edwards, director...